By Deena Beasley
| CHICAGO
CHICAGO Adding Johnson & Johnson’s Zytiga to standard hormone therapy reduced by nearly 40 percent the chance of death for men newly diagnosed with high-risk prostate cancer that had spread to other parts of the body, according to...
https://goo.gl/qr0Q5I
Saturday, 3 June 2017
Early use of J&J's Zytiga extends prostate cancer survival | Reuters
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment